Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain
In the absence of genotyping, reference exposure ranges can be used to define the dose rationale for tramadol in paediatric chronic pain. However, a starting dose of 0.5 mg/kg/day should be considered, followed by stepwise titration to the desired analgesic response.
Authors
- Paul Healy (ORCID: https://orcid.org/0000-0001-7584-7933)
- Oscar E. Della Pasqua (ORCID: https://orcid.org/0000-0002-6211-1430)
- Karel Allegaert (ORCID: https://orcid.org/0000-0001-9921-5105)
Institutions
- GlaxoSmithKline (United Kingdom) (GB)
- Erasmus MC (NL)
- University College London (GB)
- Erasmus University Rotterdam (NL)
- KU Leuven (BE)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1111/bcp.16201
- Citations
- 3
- Primary Topic
- Veterinary Pharmacology and Anesthesia
- Type
- article
- Field-Weighted Citation Impact
- 1.91
Funders
- European Commission